The base-case analysis results demonstrated that osimertinib obtained additional 0.39 QALY and $15,443.78 incremental costs compared with the comparator EGFR-TKI in the first-line treatment of advanced EGFR mutation-positive NSCLC, resulting in an ICER value of $39,369.53/QALY, higher than the WTP threshold ($37,663.26/QALY) of China. This evidence concerns the gene EGFR and non-small cell lung carcinoma.